BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8646552)

  • 21. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
    Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
    J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
    Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
    Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice.
    Nagao S; Kuriyama S; Okuda H; Tominaga K; Nakatani T; Tsujinoue H; Yoshiji H; Fukui H
    Int J Oncol; 2001 Jan; 18(1):57-65. PubMed ID: 11115539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
    Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
    J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
    Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
    Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression.
    Perlman H; Liu H; Georganas C; Woods JM; Amin MA; Koch AE; Wickham T; Kovesdi I; Mano T; Walsh K; Pope RM
    J Rheumatol; 2002 Aug; 29(8):1593-600. PubMed ID: 12180715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.
    Schowalter DB; Tubb JC; Liu M; Wilson CB; Kay MA
    Gene Ther; 1997 Apr; 4(4):351-60. PubMed ID: 9176522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors.
    Chao H; Liu Y; Rabinowitz J; Li C; Samulski RJ; Walsh CE
    Mol Ther; 2000 Dec; 2(6):619-23. PubMed ID: 11124063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors.
    Camargo FD; Huey-Louie DA; Finn AV; Sassani AB; Cozen AE; Moriwaki H; Schneider DB; Agah R; Dichek DA
    Mol Ther; 2000 Nov; 2(5):496-504. PubMed ID: 11082323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
    Manno CS; Pierce GF; Arruda VR; Glader B; Ragni M; Rasko JJ; Ozelo MC; Hoots K; Blatt P; Konkle B; Dake M; Kaye R; Razavi M; Zajko A; Zehnder J; Rustagi PK; Nakai H; Chew A; Leonard D; Wright JF; Lessard RR; Sommer JM; Tigges M; Sabatino D; Luk A; Jiang H; Mingozzi F; Couto L; Ertl HC; High KA; Kay MA
    Nat Med; 2006 Mar; 12(3):342-7. PubMed ID: 16474400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
    Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
    Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
    Bristol JA; Shirley P; Idamakanti N; Kaleko M; Connelly S
    Mol Ther; 2000 Sep; 2(3):223-32. PubMed ID: 10985953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR.
    Zhang WW; Koch PE; Roth JA
    Biotechniques; 1995 Mar; 18(3):444-7. PubMed ID: 7779393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation.
    Kojima H; Ohishi N; Yagi K
    Biochem Biophys Res Commun; 1998 May; 246(3):868-72. PubMed ID: 9618304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
    Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
    J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo.
    Kuzmin AI; Finegold MJ; Eisensmith RC
    Gene Ther; 1997 Apr; 4(4):309-16. PubMed ID: 9176516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
    Zhou H; O'Neal W; Morral N; Beaudet AL
    J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
    Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
    Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors.
    Kolls JK; Lei D; Odom G; Nelson S; Summer WR; Gerber MA; Shellito JE
    Hum Gene Ther; 1996 Mar; 7(4):489-97. PubMed ID: 8800743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.